CN104644585B - 一种阿昔洛韦药物组合物 - Google Patents
一种阿昔洛韦药物组合物 Download PDFInfo
- Publication number
- CN104644585B CN104644585B CN201510040995.9A CN201510040995A CN104644585B CN 104644585 B CN104644585 B CN 104644585B CN 201510040995 A CN201510040995 A CN 201510040995A CN 104644585 B CN104644585 B CN 104644585B
- Authority
- CN
- China
- Prior art keywords
- acyclovir
- pharmaceutical composition
- mesh
- dry
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960004150 aciclovir Drugs 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 9
- 235000020985 whole grains Nutrition 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000011122 softwood Substances 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 abstract description 8
- 230000001070 adhesive effect Effects 0.000 abstract description 8
- 239000000945 filler Substances 0.000 abstract description 7
- 239000000314 lubricant Substances 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 7
- 239000007884 disintegrant Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 3
- 239000002932 luster Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960001855 mannitol Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical group [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241001347978 Major minor Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229940016296 acyclovir oral tablet Drugs 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510040995.9A CN104644585B (zh) | 2015-01-28 | 2015-01-28 | 一种阿昔洛韦药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510040995.9A CN104644585B (zh) | 2015-01-28 | 2015-01-28 | 一种阿昔洛韦药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104644585A CN104644585A (zh) | 2015-05-27 |
CN104644585B true CN104644585B (zh) | 2018-09-18 |
Family
ID=53236560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510040995.9A Active CN104644585B (zh) | 2015-01-28 | 2015-01-28 | 一种阿昔洛韦药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104644585B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110613718A (zh) * | 2019-09-19 | 2019-12-27 | 湖北科益药业股份有限公司 | 一种缬更昔洛韦组合物 |
CN115463102B (zh) * | 2022-09-26 | 2023-11-24 | 湖北科益药业股份有限公司 | 一种阿昔洛韦片剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101002781A (zh) * | 2006-01-19 | 2007-07-25 | 上海秀新臣邦医药科技有限公司 | 盐酸伐昔洛韦片及其制备方法 |
CN101804037A (zh) * | 2009-02-13 | 2010-08-18 | 北京以岭生物工程有限公司 | 阿昔洛韦分散片及其制备方法 |
CN104042576A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种制备阿昔洛韦片剂的方法 |
-
2015
- 2015-01-28 CN CN201510040995.9A patent/CN104644585B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101002781A (zh) * | 2006-01-19 | 2007-07-25 | 上海秀新臣邦医药科技有限公司 | 盐酸伐昔洛韦片及其制备方法 |
CN101804037A (zh) * | 2009-02-13 | 2010-08-18 | 北京以岭生物工程有限公司 | 阿昔洛韦分散片及其制备方法 |
CN104042576A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种制备阿昔洛韦片剂的方法 |
Non-Patent Citations (1)
Title |
---|
阿昔洛韦分散片的制备及稳定性评价;李丙路 等;《齐鲁药事》;20071231;第26卷(第04期);第239页左栏2.1制备工艺及处方筛选、表1 * |
Also Published As
Publication number | Publication date |
---|---|
CN104644585A (zh) | 2015-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2537164T3 (es) | Forma farmacéutica unitaria que contiene tenofovir DF, emtricitabina, efavirenz y un tensioactivo | |
CN104644585B (zh) | 一种阿昔洛韦药物组合物 | |
CN102988993B (zh) | 复方对乙酰氨基酚片主要辅料的筛选和组成及其制备方法 | |
CN104958272A (zh) | 一种胃溶型薄膜包衣预混剂及其制备方法 | |
CN106727403A (zh) | 一种麦考酚钠肠溶片及其制备方法 | |
CN104523690A (zh) | 一种托匹司他口服制剂及其制备方法 | |
WO2016107361A1 (zh) | 一种含纳米SiO2的包衣剂及其制备方法 | |
CN106176771A (zh) | 一种拉米夫定‑替诺福韦复方片及其制备方法 | |
CN103768063A (zh) | 一种盐酸莫西沙星药物组合物及其制备方法 | |
US20120308656A1 (en) | Sugar-coated preparation and production method for the same | |
CN113116840A (zh) | 一种硫酸羟氯喹片的制备方法 | |
JP2009091362A (ja) | 高含量ファムシクロビル錠剤 | |
JP2009091362A6 (ja) | 高含量ファムシクロビル錠剤 | |
JPH0225428A (ja) | 苦味の軽減方法および苦味軽減組成物 | |
CN104546784B (zh) | 一种五氟利多片剂组合物及其制备方法 | |
CN104069078B (zh) | 阿托伐他汀钙药物组合物及其制备方法 | |
CN103316056A (zh) | 一种板蓝根包衣分散片及其制备方法 | |
CN105596311A (zh) | 一种利奥西呱口服固体制剂及其制备方法 | |
WO2021196982A1 (zh) | 一种抗心律失常的药物组合物及制备方法 | |
RU2318496C2 (ru) | Содержащая свехчистую флудару пероральная композиция с быстрым высвобождением действующего вещества | |
CN106692101A (zh) | 一种甲钴胺片及其制备方法 | |
CN112569197A (zh) | 一种维生素d3组合物及其制备方法和应用 | |
CN105106227A (zh) | 替诺福韦二吡呋酯的药物组合物 | |
CN107198679A (zh) | 一种蒙脱石微丸干混悬剂及其制备方法 | |
CN103784417A (zh) | 一种含硅酸镁的匹伐他汀钙片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acyclovir pharmaceutical composition Effective date of registration: 20210730 Granted publication date: 20180918 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211014 Granted publication date: 20180918 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No.8 Kangpu Avenue, high tech Industrial Park, Hanshou County, Changde City, Hunan Province, 415900 Patentee after: KAMP PHARMACEUTICALS Co.,Ltd. Address before: 12 / F, building B, Lugu information port, 658 Lugu Avenue, high tech Zone, Changsha City, Hunan Province, 410205 Patentee before: KAMP PHARMACEUTICALS Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acyclovir pharmaceutical composition Effective date of registration: 20211028 Granted publication date: 20180918 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |